Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionGryphon Financial Partners LLC
Latest Disclosed Ownership1,856 shares
Latest Disclosed Value $ 828,779
Gryphon Financial Partners LLC reports 2.06% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 6, 2026 - Gryphon Financial Partners LLC filed a 13F-HR form disclosing ownership of 1,856 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $828,778 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 8, 2026 disclosing 1,895 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -2.06% during the quarter. The current value of the position is $829,316 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,856 -39 -2.06 829 -3.61 0.0660
2026-01-08 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,895 -12 -0.63 859 15.15 0.0919
2025-11-12 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,907 784 69.81 747 49.50 0.0852
2025-08-07 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,123 5 0.45 500 -7.93 0.0653
2025-05-12 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,118 64 6.07 542 27.83 0.0782
2025-02-06 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,054 -815 -43.61 424 -51.21 0.0606
2024-11-08 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,869 316 20.35 869 19.53 0.1175
2024-08-07 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,553 -9 -0.58 728 11.50 0.1090
2024-05-01 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,562 -416 -21.03 653 34.16 0.1085
2024-02-13 2023-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 1,978 414 26.47 486 -10.50 0.0859
2024-02-06 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,978 414 486 0.0339
2023-11-07 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,564 -1 -0.06 544 -1.27 0.1262
2023-08-08 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,565 26 1.69 551 13.64 0.1192
2023-05-03 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,539 6 0.39 485 9.50 0.1103
2023-02-08 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,533 -2 -0.13 443 -0.67 0.1054
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,535 17 1.12 445 3.97 0.1121
2022-07-28 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,518 -3 -0.20 428 8.08 0.1039
2022-05-05 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,521 -74 -4.64 396 13.14 0.0806
2022-02-01 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,595 -167 -9.48 350 9.38 0.0663
2021-11-12 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,762 -178 -9.18 320 -36.38 0.0711
2021-08-13 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,940 42 2.21 503 23.59 0.1131
2021-05-05 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,898 10 0.53 407 -8.74 0.0925
2021-02-10 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,888 -20 -1.05 446 -14.56 0.1149
2020-11-16 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,908 20 1.06 522 -4.74 0.1542
2020-08-13 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,888 -166 -8.08 548 12.30 0.1699
2020-05-05 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,054 -127 -5.82 488 2.09 0.1797
2020-02-06 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,181 21 0.97 478 30.60 0.1240
2019-11-07 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,160 -5 -0.23 366 -7.81 0.1056
2019-08-09 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,165 -7 -0.32 397 -0.50 0.1143
2019-05-07 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,172 -8 -0.37 399 10.53 0.1177
2019-02-11 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,180 -32 -1.45 361 -15.46 0.0918
2018-11-06 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,212 1,974 829.41 427 967.50 0.1274
2018-08-14 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 238 -10 -4.03 40 -2.44 0.0181
2018-05-14 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 248 2 0.81 41 10.81 0.0210
2018-02-09 2017-12-31 13F VERTEX PHARMACEUTICALS I COM 92532F100 246 246 37 0.0210
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.